tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Mar 3;1-6.
doi: 10.1080/21645515.2022.2045857. Online ahead of print.
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Etsuro Nanishi[SUP] 1 2 [/SUP], Ofer Levy[SUP] 1 2 3 [/SUP], Al Ozonoff[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.
Keywords: COVID-19; Vaccine; effectiveness; older adults; waning.
. 2022 Mar 3;1-6.
doi: 10.1080/21645515.2022.2045857. Online ahead of print.
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Etsuro Nanishi[SUP] 1 2 [/SUP], Ofer Levy[SUP] 1 2 3 [/SUP], Al Ozonoff[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 35240940
- DOI: 10.1080/21645515.2022.2045857
Abstract
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.
Keywords: COVID-19; Vaccine; effectiveness; older adults; waning.